Immune Response News and Research

RSS

Study points to new treatment strategies for liver cancer

A new study by researchers at Sanford Burnham Prebys Medical Discovery Institute, the National Cancer Institute, and the Chulabhorn Research Institute has found that blocking the activity of a key immune receptor, the lymphotoxin-beta receptor (LTβR), reduces the progression of liver cancer.

25 Jul 2015

Genetic variation influences survival in patients with multiple myeloma

As part of a multi-institutional effort, researchers with Huntsman Cancer Institute at the University of Utah have found that multiple myeloma patients with a genetic variation in the gene FOPNL die on average 1-3 years sooner than patients without it.

23 Jul 2015

AS03 and MF59 adjuvants increase immune responses to two doses of H7N9 influenza vaccine

In a phase 2 trial that included nearly 1,000 adults, the AS03 and MF59 adjuvants (a component that improves immune response of inactivated influenza vaccines) increased the immune responses to two doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest amount of antibody response, according to a study in the July 21 issue of JAMA.

22 Jul 2015

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax, a biopharmaceutical company specialized in research and development of therapeutic and diagnostic solutions for major infectious and chronic diseases, today announced the overall results of its Phase I/IIa clinical study of its VAC-3S immunotherapy, which is currently in development.

22 Jul 2015

Researchers devise way to induce protective immunity in mice against influenza viruses

A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain.

22 Jul 2015

Alefacept drug offers clinical benefit to certain individuals with new-onset type 1 diabetes

Individuals with new-onset type 1 diabetes who took two courses of alefacept (Amevive®, Astellas Pharma Inc.) soon after diagnosis show preserved beta cell function after two years compared to those who received a placebo.

21 Jul 2015

Duke study finds that gut worms can protect babies' brains from chronic inflammation

A Duke University study in rats finds that gut worms can protect babies' brains from long-term learning and memory problems caused by newborn infections.

21 Jul 2015

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug recently shown to reverse two other disfiguring skin conditions, vitiligo and alopecia areata. The study is evidence of a potential new era in eczema treatment, they report.

21 Jul 2015

New study may help identify novel ways to treat immune thrombocytopenia

Immune thrombocytopenia, or ITP, is an autoimmune disease whereby the immune system sends antibodies to attack and destroy the body's platelets--blood cells responsible for controlling bleeding.

20 Jul 2015

Proteins responsible for controlling iron levels in the body also fight against infection

Proteins responsible for controlling levels of iron in the body also play an important role in combatting infection, according to a study published today in Cell Host & Microbe.

17 Jul 2015

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.

15 Jul 2015

Oxford University performs second phase of experimental Ebola vaccine trial

Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert and the Janssen Pharmaceutical Companies of Johnson & Johnson.

15 Jul 2015

New review article explains link between PTSD and increased cardiovascular disease risk

A growing number of patient studies show that people who suffered post-traumatic stress disorder (PTSD) are at a higher risk of developing cardiovascular diseases, including stroke and heart attack. A new review article in American Journal of Physiology—Regulatory, Integrative and Comparative Physiology examines the recent scientific literature to explain how the two are linked.

15 Jul 2015

Ebola vaccine study begins in Dakar, Senegal

A trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial immunisations started at the Jenner Institute, Oxford University. The announcement comes as a conference in Oxford discusses the global response to Ebola and the implications for future drug and vaccine development.

15 Jul 2015

New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

New research from the Johns Hopkins Bloomberg School of Public Health suggests that the protein keratin 17 - the presence of which is used in the lab to detect and stage various types of cancers - is not just a biomarker for the disease, but may play a critical role in tumor growth.

14 Jul 2015

Researchers identify protein responsible for preserving antibody-producing cells that lead to long-term immunity

Melbourne researchers have identified a protein responsible for preserving the antibody-producing cells that lead to long-term immunity after infection or vaccination.

14 Jul 2015

Activating bacterial receptors boosts macrophage response, limits damage to spinal cord following injury

Macrophages are cellular sentinels in the body, assigned to identify "attacks" from viruses, bacteria, or fungi and sound the alarm when they are present. However, these cells are a "double edged sword" in spinal cord injury, providing both neural repair-promoting properties and pathological functions that destroy neuronal tissue

13 Jul 2015

Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others.

13 Jul 2015

Microbiota blocks the immune cells responsible for triggering allergies

The human body is inhabited by billions of symbiotic bacteria, carrying a diversity that is unique to each individual. The microbiota is involved in many mechanisms, including digestion, vitamin synthesis and host defense.

12 Jul 2015

Cedars-Sinai researchers test new methods for preserving cognition in laboratory mice

Cedars-Sinai researchers have successfully tested two new methods for preserving cognition in laboratory mice that exhibit features of Alzheimer's disease by using white blood cells from bone marrow and a drug for multiple sclerosis to control immune response in the brain.

8 Jul 2015

Immune Response News and Research

Study points to new treatment strategies for liver cancer

Genetic variation influences survival in patients with multiple myeloma

AS03 and MF59 adjuvants increase immune responses to two doses of H7N9 influenza vaccine

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

Researchers devise way to induce protective immunity in mice against influenza viruses

Alefacept drug offers clinical benefit to certain individuals with new-onset type 1 diabetes

Duke study finds that gut worms can protect babies' brains from chronic inflammation

Researchers successfully treat eczema patients using rheumatoid arthritis drug

New study may help identify novel ways to treat immune thrombocytopenia

Proteins responsible for controlling iron levels in the body also fight against infection

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Oxford University performs second phase of experimental Ebola vaccine trial

New review article explains link between PTSD and increased cardiovascular disease risk

Ebola vaccine study begins in Dakar, Senegal

New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

Researchers identify protein responsible for preserving antibody-producing cells that lead to long-term immunity

Activating bacterial receptors boosts macrophage response, limits damage to spinal cord following injury

Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Microbiota blocks the immune cells responsible for triggering allergies

Cedars-Sinai researchers test new methods for preserving cognition in laboratory mice

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News